Description of Research Expertise:
Cancer immunotherapy
Vaccines
Cellular therapy
Phase I trials
CAR T cells
Selected Publications:
Gumber Ramnika, Cohen Jordana B, Palmer Matthew B, Kobrin Sidney M, Vogl Dan T, Wasserstein Alan G, Nasta Sunita D, Bleicher Melissa B, Bloom Roy D, Dember Laura, Cohen Adam, Weiss Brendan M, Hogan Jonathan J: A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Kidney international 94 (1): 199-205,2018.
Cohen Adam D: CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting (38): e6-e15,2018.
Garfall Alfred L, Stadtmauer Edward A, Hwang Wei-Ting, Lacey Simon F, Melenhorst Jan Joseph, Krevvata Maria, Carroll Martin P, Matsui William H, Wang Qiuju, Dhodapkar Madhav V, Dhodapkar Kavita, Das Rituparna, Vogl Dan T, Weiss Brendan M, Cohen Adam D, Mangan Patricia A, Ayers Emily C, Nunez-Cruz Selene, Kulikovskaya Irina, Davis Megan M, Lamontagne Anne, Dengel Karen, Kerr Naseem Ds, Young Regina M, Siegel Donald L, Levine Bruce L, Milone Michael C, Maus Marcela V, June Carl H: Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI insight 3 (8): 2018.
Waxman Adam J, Clasen Suparna, Hwang Wei-Ting, Garfall Alfred, Vogl Dan T, Carver Joseph, O'Quinn Rupal, Cohen Adam D, Stadtmauer Edward A, Ky Bonnie, Weiss Brendan M: Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. JAMA oncology 4 (3): e174519,2018.
Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson Jr. LD, Sutherland HJ, Yong K, Hoos A, Gorczyca MM, Lahiri S, He Z, Austin DJ, Opalinska JB, Cohen AD: Targeting B-Cell Maturation Antigen with GSK2857916 Antibody-Drug Conjugate in Relapsed or Refractory Multiple Myeloma: A Dose-Escalation and Expansion Phase 1 Trial (BMA117159) Lancet Oncology : in press,2018.
Campbell KS, Cohen AD, Pazina T: Dissecting the Mechanism of NK Cell Activation by the SLAMF7 Antibody, Elotuzumab Frontiers in Immunology : in press,2018.
Shah Jatin J, Kaufman Jonathan L, Zonder Jeffrey A, Cohen Adam D, Bensinger William I, Hilder Brandi W, Rush Selena A, Walker Duncan H, Tunquist Brian J, Litwiler Kevin S, Ptaszynski Mieke, Orlowski Robert Z, Lonial Sagar: A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma. Cancer 123 (23): 4617-4630,2017.
David C Fajgenbaum, Dustin Shilling, Helen L Partridge, Sheila K Pierson, Jason R Ruth, Christopher Sheild Nabel, Katie Stone, Vandana Chaturvedi, Michael B. Jordan, Adam D. Cohen, Vera Krymskaya, Arthur H Rubenstein, Frits van Rhee, and Thomas S Uldrick: Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach Blood (ASH Annual Meeting) 130 : #3593,2017.
Pazina Tatiana, James Ashley M, MacFarlane Alexander W, Bezman Natalie A, Henning Karla A, Bee Christine, Graziano Robert F, Robbins Michael D, Cohen Adam D*, Campbell Kerry S*: The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms. Oncoimmunology 6 (9): e1339853,2017.
Adam D. Cohen, Alfred L. Garfall, Edward A. Stadtmauer, Simon F Lacey, Eric Lancaster, Dan T. Vogl, Brendan M Weiss, David E Ambrose, Anne Marie Nelson, Fang Chen, Gabriela Plesa, Irina Kulikovskaya, Vanessa Gonzalez, Minnal Gupta, Regina M Young, Karen Dengel, Laura O'keefe, Samantha Le, Celeste Richardson, Randi E. Isaacs, J. Joseph Melenhorst, Bruce L Levine, Carl H June, and Michael C. Milone: Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM) Blood (ASH Annual Meeting) 130 : #505,2017.